BMRA Overview

Biomerica, Inc. is a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are utilized in the analysis of blood, urine, nasal, or fecal samples for the diagnosis of various diseases, food intolerances, and other medical conditions. Its range of medical diagnostic products is sold primarily in two markets: clinical laboratories and point-of-care settings, including physicians’ offices and over-the-counter sales. It is focused on research and development efforts and is its patented diagnostic-guided therapy (DGT) product, developed on the in Foods technology platform. Its inFoods IBS product, uses a simple blood test to identify patient-specific foods that, when eliminated, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping, and constipation. Its hp+detect, a new diagnostic test for detecting Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract.

Wall Street analysts forecast BMRA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMRA is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Biomerica Inc revenue for the last quarter amounts to 1.21M USD, decreased -26.04

Biomerica Inc. EPS for the last quarter amounts to -0.45 USD, increased 2.27

Biomerica Inc (BMRA) has 53 emplpoyees as of March 12 2026.

Today BMRA has the market capitalization of 6.10M USD.